Technology transfer

Liberty Defense Holdings Ltd. Discusses HEXWAVE Beta Testing and Commercialization with The Stock Day Podcast

Thursday, October 14, 2021 - 2:03pm

"We have three products; HEXWAVE being our flagship, as well as two other technologies we are developing."

Key Points: 
  • "We have three products; HEXWAVE being our flagship, as well as two other technologies we are developing."
  • Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies.
  • Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets.
  • The Stock Day Podcast is the number one radio show of its kind in America.

Tekcapital Plc Provides Update on Portfolio Company Salarius, Ltd.

Thursday, October 14, 2021 - 1:35pm

Tekcapital owns 97.2% of the share capital of Salarius Ltd. and 87.1% of the share capital of MicroSalt Inc., its U.S. subsidiary.

Key Points: 
  • Tekcapital owns 97.2% of the share capital of Salarius Ltd. and 87.1% of the share capital of MicroSalt Inc., its U.S. subsidiary.
  • Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK.
  • No assurance is given that such forward looking statements or views are correct or that the objectives of the Company will be achieved.
  • Tekcapital neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which may differ from those anticipated.

Embedded Ventures Announces 'First of its Kind' Cooperative Research and Development Agreement with United States Space Force

Wednesday, October 13, 2021 - 2:30pm

MALIBU, Calif., Oct. 13, 2021 /PRNewswire/ -- Embedded Ventures , a new venture capital firm investing in dual-use space startups beyond launch, today announced an unprecedented multi-year agreement with United States Space Force (USSF)'s SpaceWERX office.

Key Points: 
  • MALIBU, Calif., Oct. 13, 2021 /PRNewswire/ -- Embedded Ventures , a new venture capital firm investing in dual-use space startups beyond launch, today announced an unprecedented multi-year agreement with United States Space Force (USSF)'s SpaceWERX office.
  • We are honored to partake in the first formal VC partnership with USSF," said Jenna Bryant, Co-Founder, CEO and General Partner of Embedded Ventures.
  • "From the moment I met Jenna, Jordan and Mandy, I knew they were the right team to launch this unique cooperative research and development agreement.
  • "Space is inherently different in that it leverages commercial industry as an integral part of every space capability," said Mandy Vaughn, Operating Partner at Embedded Ventures.

The Korea Herald introduces: Carbon Neutral EXPO held from October 13 to 15

Tuesday, October 12, 2021 - 10:31am

SEOUL, Oct. 12, 2021 /PRNewswire/ Following announcement covered by koreaherald.com, the Ministry of Trade, Industry and Energy (MOTIE) announced that it will host the "Carbon Neutral EXPO," Korea's largest energy exhibition, from October 13 to 15 at KINTEX in Gyeonggi Province, South Korea.

Key Points: 
  • SEOUL, Oct. 12, 2021 /PRNewswire/ Following announcement covered by koreaherald.com, the Ministry of Trade, Industry and Energy (MOTIE) announced that it will host the "Carbon Neutral EXPO," Korea's largest energy exhibition, from October 13 to 15 at KINTEX in Gyeonggi Province, South Korea.
  • The EXPO will be co-hosted with Korea Energy Show 2021, which marks its 40th anniversary this year.
  • 297 organizations and businesses will participate in the Expo and promote their carbon-neutral products and technologies.
  • They also join networking programs offered by foreign embassies to Korea and local governments to find domestic and international markets.

Sai Life Sciences presents mid-term report on Sai Nxt initiative; reveals upsurge in capabilities

Monday, October 11, 2021 - 9:31am

HYDERABAD, India, Oct. 11, 2021 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development and Manufacturing Organisation (CRO-CDMO), today presented a midterm report on its organizational transformative initiative, Sai Nxt. Envisaged as a 4-year program from 2019 to 2023 with an investment target of US$150M, Sai Nxt has enabled a transformation in the company's capabilities across three core areas: (1) People & culture (2) Processes & automation (3) Infrastructure & scientific capabilities.

Key Points: 
  • CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri, said, "At the halfway mark of Sai Nxt, we have completed two-thirds of our committed investment.
  • Guided by the insights and feedback from its innovator customers, Sai Life Sciences has expanded its R&D and manufacturing facilities , deepened scientific & technological capabilities , strengthened automation and data systems, and raised the bar for safety, quality and customer focus.
  • Sai Life Sciences is a full-service CRO-CDMO that works with innovator pharma and biotech companies globally, to accelerate the discovery, development and commercialisation of complex small molecules.
  • Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments.

Sai Life Sciences presents mid-term report on Sai Nxt initiative; reveals upsurge in capabilities

Monday, October 11, 2021 - 9:39am

HYDERABAD, India, Oct. 11, 2021 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development and Manufacturing Organisation (CRO-CDMO), today presented a midterm report on its organizational transformative initiative, Sai Nxt. Envisaged as a 4-year program from 2019 to 2023 with an investment target of US$150M, Sai Nxt has enabled a transformation in the company's capabilities across three core areas: (1) People & culture (2) Processes & automation (3) Infrastructure & scientific capabilities.

Key Points: 
  • CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri, said, "At the halfway mark of Sai Nxt, we have completed two-thirds of our committed investment.
  • More importantly, it has augmented our ability to serve the needs of global pharma and biotech innovators withspeed, compliance and dependability."
  • Sai Life Sciences is a full-service CRO-CDMO that works with innovator pharma and biotech companies globally, to accelerate the discovery, development and commercialisation of complex small molecules.
  • Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments.

World Green Economy Summit 2021 concludes with 7th Dubai Declaration

Monday, October 11, 2021 - 7:00am

Dubai, UAE, Oct. 11, 2021 /PRNewswire/ -- Under the theme'Galvanising Action for a Sustainable Recovery,'Dubai Electricity and Water Authority (DEWA) and the World Green Economy Organization organised 7th World Green Economy Summit (WGES).

Key Points: 
  • Dubai, UAE, Oct. 11, 2021 /PRNewswire/ -- Under the theme'Galvanising Action for a Sustainable Recovery,'Dubai Electricity and Water Authority (DEWA) and the World Green Economy Organization organised 7th World Green Economy Summit (WGES).
  • It brought together prominent speakers and officials and was centred aroundfour themes: Youth; Innovation and Smart Technologies; Green Economy and Policies; and Green Finance.
  • WGES concluded with HE Saeed Mohammed Al Tayer, Vice Chairman of the Dubai Supreme Council of Energy, MD&CEO of DEWA, and Chairman of WGES, announcing Dubai Declaration 2021.
  • This will coincide with the next World Green Economy Summit in Expo 2020 Dubai in March 2022.

World Green Economy Summit 2021 concludes with 7th Dubai Declaration

Monday, October 11, 2021 - 7:00am

Dubai, UAE, Oct. 11, 2021 /PRNewswire/ -- Under the theme'Galvanising Action for a Sustainable Recovery,'Dubai Electricity and Water Authority (DEWA) and the World Green Economy Organization organised 7th World Green Economy Summit (WGES).

Key Points: 
  • Dubai, UAE, Oct. 11, 2021 /PRNewswire/ -- Under the theme'Galvanising Action for a Sustainable Recovery,'Dubai Electricity and Water Authority (DEWA) and the World Green Economy Organization organised 7th World Green Economy Summit (WGES).
  • It brought together prominent speakers and officials and was centred aroundfour themes: Youth; Innovation and Smart Technologies; Green Economy and Policies; and Green Finance.
  • WGES concluded with HE Saeed Mohammed Al Tayer, Vice Chairman of the Dubai Supreme Council of Energy, MD&CEO of DEWA, and Chairman of WGES, announcing Dubai Declaration 2021.
  • This will coincide with the next World Green Economy Summit in Expo 2020 Dubai in March 2022.

Rapid Growth in Drug Discovery and New Therapy Research Spurring Sales of Chromatographic Separation Resins to reach 2x by 2031

Thursday, October 7, 2021 - 12:30pm

Demand for therapeutic treatments such as Alzheimer's and inflammatory disorders as well as autoimmune disorders has resulted in increased application of chromatographic separation resins for efficient production processes in drug development.

Key Points: 
  • Demand for therapeutic treatments such as Alzheimer's and inflammatory disorders as well as autoimmune disorders has resulted in increased application of chromatographic separation resins for efficient production processes in drug development.
  • Opportunistic growth awaits key players in terms of new drug development and patent protection of biologic drugs.
  • The opportunity for development of biosimilars due to this factor will lead to higher process demand for chromatographic separation resins over the coming years.
  • Get customized report by asking an expert: https://www.persistencemarketresearch.com/ask-an-expert/32828
    "Advancements in technology and application of chromatographic separation resins in drug discovery are anticipated to drive market expansion," says an analyst of Persistence Market Research.

Rapid Growth in Drug Discovery and New Therapy Research Spurring Sales of Chromatographic Separation Resins to reach 2x by 2031

Thursday, October 7, 2021 - 12:30pm

Demand for therapeutic treatments such as Alzheimer's and inflammatory disorders as well as autoimmune disorders has resulted in increased application of chromatographic separation resins for efficient production processes in drug development.

Key Points: 
  • Demand for therapeutic treatments such as Alzheimer's and inflammatory disorders as well as autoimmune disorders has resulted in increased application of chromatographic separation resins for efficient production processes in drug development.
  • Opportunistic growth awaits key players in terms of new drug development and patent protection of biologic drugs.
  • The opportunity for development of biosimilars due to this factor will lead to higher process demand for chromatographic separation resins over the coming years.
  • Get customized report by asking an expert: https://www.persistencemarketresearch.com/ask-an-expert/32828
    "Advancements in technology and application of chromatographic separation resins in drug discovery are anticipated to drive market expansion," says an analyst of Persistence Market Research.